PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
289 / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-96.92%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-102.97%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-144.64%
Negative EBIT growth while ECL.AX is at 451.99%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-144.64%
Negative operating income growth while ECL.AX is at 451.99%. Joel Greenblatt would press for urgent turnaround measures.
-113.30%
Negative net income growth while ECL.AX stands at 494.52%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.90%
Share reduction while ECL.AX is at 0.17%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.00%
Negative OCF growth while ECL.AX is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
22.84%
FCF growth of 22.84% while ECL.AX is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.32%
AR growth of 1.32% while ECL.AX is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-40.65%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-74.37%
We’re deleveraging while ECL.AX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
100.34%
R&D growth of 100.34% while ECL.AX is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
-66.59%
We cut SG&A while ECL.AX invests at 29.48%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.